Previous 10 | Next 10 |
home / stock / pali / pali articles
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This...
With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Sacks Parente ...
Palisade Bio Inc (NASDAQ: PALI) shares are trading lower by 6.1% to $0.69 Tuesday morning. The stock is trading lower on downward momentu...
Palisade Bio Inc (NASDAQ: PALI) shares are trading lower by 0.66% to $0.75 Monday morning on downward momentum after the company last wee...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 40 points on Thursday. The Dow traded up 0.12% to 34,483.80 w...
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 100% to $1.7909 after the company's subsidiary Champion Safe has been bomba...
Palisade Bio Inc (NASDAQ: PALI) shares are trading lower by 46% to $0.78 Thursday morning after the company announced a $2 million registered ...
U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling around 200 points on Thursday. The Dow traded up 0.12% to...
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 200 points on Thursday. Following the market opening Thur...
News, Short Squeeze, Breakout and More Instantly...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative selection strategy dev...
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisad...